

# Invesco NASDAQ Future Gen 200 ETF

As of December 31, 2022



## Fund description

The Invesco NASDAQ Future Gen 200 ETF (Fund) is based on the Nasdaq Innovators Completion Cap Index (Index). The Fund will invest at least 90% of its total assets in the securities that comprise the Index. The Index consists of 200 small-cap companies with the most valuable patent portfolios relative to their total market value as deemed by Nasdaq. The eligible universe consists of the companies within the Nasdaq Composite Index, excluding those companies included in the Nasdaq-100 Index and Nasdaq Next Generation 100 Index. Each constituent within the Index is equally weighted. The Fund and Index are rebalanced quarterly and reconstituted semi-annually.

## ETF Information

Fund Name	Invesco NASDAQ Future Gen 200 ETF
Fund Ticker	QQQS
CUSIP	46138G482
Intraday NAV	QQQSIV
30 Day SEC Unsubsidized Yield	-
30 day SEC Yield	-
Holdings	200
Management Fee	0.20%
Total Expense Ratio	0.20%
P/B Ratio	4.37
P/E Ratio	5.90
Return on Equity	-38.65%
Listing Exchange	Nasdaq
Weighted Market Cap (\$MM)	1,565.10

## Underlying Index Data

Index Provider	Nasdaq, Inc.
Index Name	Nasdaq Innovators Completion Cap Index
Index Ticker	NCXT

## Performance as at December 31, 2022

Performance (%)	YTD	1Y	3Y	5Y	10Y	Fund Inception
ETF - NAV	-	-	-	-	-	6.67
ETF - Market Price	-	-	-	-	-	6.59
Underlying Index	-	-	-	-	-	6.81
Benchmark <sup>1</sup>	-32.54	-32.54	6.10	9.67	14.43	-1.49
Benchmark <sup>2</sup>	-20.44	-20.44	3.10	4.13	9.01	2.28

*This is a new Fund and has no full-year Fund performance to report as of most recent quarter end. Returns less than one year are cumulative. Performance data quoted represents past performance. Past performance is not a guarantee of future results; current performance may be higher or lower than performance quoted. Investment returns and principal value will fluctuate and Shares, when redeemed, may be worth more or less than their original cost. See [invesco.com](https://www.invesco.com) to find the most recent month-end performance numbers. Market returns are based on the midpoint of the bid/ask spread at 4 p.m. ET and do not represent the returns an investor would receive if shares were traded at other times. Fund performance reflects fee waivers, absent which, performance data quoted would have been lower.*

## Fund inception: October 13, 2022

Not a Deposit Not FDIC Insured Not Guaranteed by the Bank May Lose Value Not Insured by any Federal Government Agency

Shares are not individually redeemable and owners of the Shares may acquire those Shares from the Fund and tender those Shares for redemption to the Fund in Creation Unit aggregations only, typically consisting of 10,000 Shares.

Index returns do not represent Fund returns. An investor cannot invest directly in an index.


Neither the underlying Index nor the benchmark indexes charge management fees or brokerage expenses, and no such fees or expenses were deducted from the performance shown; nor do any of the indexes lend securities, and no revenues from securities lending were added to the performance shown. In addition, the results actual investors might have achieved would have differed from those shown because of differences in the timing, amounts of their investments, and fees and expenses associated with an investment in the Fund.

<sup>1</sup>The NASDAQ Composite Index measures all NASDAQ domestic and international-based common stocks listed on The Nasdaq Stock Market.

<sup>2</sup>The Russell 2000<sup>®</sup> Index measures the performance of the small-cap segment of the US equity universe. The Russell 2000<sup>®</sup> Index is a trademark/service mark of the Frank Russell Co. Russell<sup>®</sup> is a trademark of the Frank Russell Co.


Top ETF holdings (%)	
(Total holdings: 200)	
Name	Weight
Madriral Pharmaceuticals	2.10
Rigel Pharmaceuticals	1.13
Cymabay Therapeutics	0.94
Ardelyx	0.84
Altimune	0.84
PDS Biotechnology	0.75
Oramed Pharmaceuticals	0.73
Protagonist Therapeutics	0.70
Tactile Systems Technology	0.68
Liquidia	0.64

#### Geographic allocation (%)



United States	93.08
Israel	1.21
China	1.06
Canada	0.96
Netherlands	0.95
Switzerland	0.55
Ireland	0.53
Singapore	0.47
Belgium	0.47
Taiwan	0.43

#### Sector allocation (%)



Health Care	55.46
Information Technology	27.65
Consumer Discretionary	8.29
Industrials	3.93
Communication Services	2.31
Materials	1.39
Energy	0.59
Consumer Staples	0.40

#### Investment risks

There are risks involved with investing in ETFs, including possible loss of money. Shares are not actively managed and are subject to risks similar to those of stocks, including those regarding short selling and margin maintenance requirements. Ordinary brokerage commissions apply. The Fund's return may not match the return of the Underlying Index. The Fund is subject to certain other risks. Please see the current prospectus for more information regarding the risk associated with an investment in the Fund.

The risks of investing in securities of foreign issuers can include fluctuations in foreign currencies, political and economic instability, and foreign taxation issues.

Investments focused in a particular sector, such as information technology and health care, are subject to greater risk, and are more greatly impacted by market volatility, than more diversified investments.

Stocks of small and mid-sized companies tend to be more vulnerable to adverse developments, may be more volatile, and may be illiquid or restricted as to resale.

The Fund's Underlying Index (Index) is composed of companies with valuable portfolios of patents. The Index Provider relies on an independent data provider to ascertain the potential value of an issuer's patents and related intangible assets (i.e., intellectual property and research & development activities) for inclusion in the Index. The Fund's performance may suffer if the data provider's does not correctly value holding such patents. There is no guarantee that the Index will be composed of companies with the most valuable an issuer's patents or if the companies included in the Index ultimately do not benefit from patents.

The Fund is non-diversified and may experience greater volatility than a more diversified investment.

#### Important information

Typically, security classifications used in calculating allocation tables are as of the last trading day of the previous month.

This does not constitute a recommendation of any investment strategy or product for a particular investor. Investors should consult a financial professional before making any investment decisions.

The Invesco NASDAQ Future Gen 200 ETF is not sponsored, endorsed, sold or promoted by the NASDAQ OMX Group, Inc. or its affiliates (NASDAQ OMX, with its affiliates, are referred to as the "Corporations"). The Corporations have no liability in connection with the administration, marketing or trading of the Invesco NASDAQ Future Gen 200 ETF. "NASDAQ<sup>®</sup>" is a registered trademark and is used under license.

**Before investing, investors should carefully read the prospectus and consider the investment objectives, risks, charges and expenses. For this and more complete information about the fund, investors should ask their financial professionals for a prospectus or download one at [invesco.com](http://invesco.com)**

Note: Not all products available through all firms or in all jurisdictions.

#### Glossary

**30 Day SEC Unsubsidized Yield** reflects the 30-day yield if the investment adviser were not waiving all or part of its fee or reimbursing the fund for part of its expenses. Total return would have also been lower in the absence of these temporary reimbursements or waivers.

**30 Day SEC Yield** is based on a 30-day period and is computed by dividing the net investment income per share earned during the period by the maximum offering price per share on the last day of the period.